Division of Nephrology, Hammersmith Hospital, Imperial College Healthcare, NHS, London, UK.
Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY.
Adv Kidney Dis Health. 2024 Jul;31(4):346-357. doi: 10.1053/j.akdh.2024.04.008.
Paraneoplastic glomerular disease (PGD) develops from tumor cell products, leading to renal dysfunction. Unlike direct tumor effects, PGD illustrates the complex association between cancer and diverse clinical presentations and outcomes. Initially detected in a Hodgkin's disease patient, current research has defined diagnostic criteria based on PGD symptoms and cancer progression. PGDs, although rare (found in <1% of adult cancer patients with overt renal manifestations), are crucial, as they can signal cancer onset and frequently resist standard glomerulonephritis treatments. The emerging field of onconephrology studies this relationship between kidney disorders and cancers. The exact cause of many PGD cases remains unknown. This review examines PGDs, their clinicopathological features, related cancers, and mechanisms, emphasizing the need for early diagnosis and tailored treatment for kidney disease and linked cancer.
副肿瘤性肾小球疾病 (PGD) 由肿瘤细胞产物引起，导致肾功能障碍。与直接的肿瘤作用不同，PGD 说明了癌症与多种临床表现和结局之间的复杂关联。最初在霍奇金病患者中发现，目前的研究已根据 PGD 症状和癌症进展定义了诊断标准。PGD 虽然罕见（在有明显肾脏表现的成年癌症患者中 <1%），但很重要，因为它们可以提示癌症的发生，并且经常对标准的肾小球肾炎治疗产生抵抗。新兴的肿瘤肾脏病学领域研究了肾脏疾病和癌症之间的这种关系。许多 PGD 病例的确切原因仍不清楚。本综述探讨了 PGD 的临床病理特征、相关癌症及其机制，强调了早期诊断和针对肾脏疾病和相关癌症的个体化治疗的必要性。
